Crizotinib with Daridorexant Interaction Details


Brand Names Associated with Crizotinib

  • Crizotinib
  • Xalkori®

Brand Names Associated with Daridorexant

  • Daridorexant
  • QUVIVIQ®

Medical Content Editor
Last updated Mar 07, 2024


Curious for more information about this interaction?

Ask our pharmacists directly!

Reach out to us

Interaction Effect

Increased daridorexant and CYP3A4 substrate with NTI exposure


Interaction Summary

Concomitant use of daridorexant (CYP3A4 substrate) with a moderate CYP3A4 inhibitor which is also a CYP3A4 substrate with NTI as it increases exposure to daridorexant and CYP3A4 substrate with NTI, which may increase the risk of adverse reactions. If used concomitantly, use caution and do not exceed daridorexant dose of 25 mg once per night[1].


Severity

Major


Onset

Unspecified


Evidence

Probable


How To Manage Interaction

Concomitant use of daridorexant (CYP3A4 substrate) with a moderate CYP3A4 inhibitor which is also a CYP3A4 substrate with NTI as it increases exposure to daridorexant and CYP3A4 substrate with NTI, which may increase the risk of adverse reactions. If used concomitantly, use caution and do not exceed daridorexant dose of 25 mg once per night[1].


Mechanism Of Interaction

Inhibition of CYP3A4-mediated metabolism of daridorexant; inhibition of CYP3A4-substrate metabolism by daridorexant


Literature Reports

A) Concomitant use of daridorexant 25 mg and dilTIAZem (moderate CYP3A4 inhibitor) 240 mg increased daridorexant AUC by a geometric mean ratio (GMR) of 2.4 (90% CI, 2 to 2.8) and Cmax by a GMR of 1.4 (90% CI, 1.2 to 1.6) [1].

B) Concomitant use of single dose daridorexant 50 mg and midazolam (CYP3A4 substrate) 2 mg increased daridorexant AUC by a geometric mean ratio (GMR) of 1.4 (90% CI, 1.3 to 1.6) and Cmax by a GMR of 1.1 (90% CI, 1.0 to 1.3) [1].

References

    1 ) Product Information: QUVIVIQ(R) oral tablets, daridorexant oral tablets. Idorsia Pharmaceuticals US Inc (per FDA), Radnor, PA, 2023.

Crizotinib Overview

  • Crizotinib is used to treat certain types of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body. It is also used to treat a certain type of anaplastic large cell lymphoma (ALCL) that has returned or is unresponsive to other treatment(s) in certain adults and children 1 year of age and older. Crizotinib is also used to treat a certain type of inflammatory myofibroblastic tumor (IMT; type of cancer that occurs in mucosal tissues usually in the abdominal area, involving the lungs, bladder, stomach, uterus, liver, or intestines) that cannot be treated with surgery or that has not improved or has come back after previous treatment(s) in adults and children 1 year of age and older. Crizotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.

See More information Regarding Crizotinib

Daridorexant Overview

  • Daridorexant is used to treat insomnia (difficulty falling asleep or staying asleep). Daridorexant is in a class of medications called orexin receptor antagonists. It works by blocking the action of a certain natural substance in the brain that causes wakefulness.

See More information Regarding Daridorexant

Return To Our Drug Interaction Homepage


Feedback, Question Or Comment About This Information?

Ask , our medical editor, directly! He's always more than happy to assist.


Definitions

Severity Categories

Contraindicated

These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.


Major

This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.


Moderate

This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.


Minor

While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.


Onset

Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.

Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.


Evidence

Level of documentation of the interaction.

Established: The interaction is documented and substantiated in peer-reviewed medical literature.

Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.


How To Manage The Interaction

Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.

It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.


Mechanism Of Interaction

The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.


Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.

Where Does Our Information Come From?

Information for our drug interactions is compiled from several drug compendia, including:

The prescribing information for each drug, as published on DailyMED, is also used. 

Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.

The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.